ZyVersa Therapeutics, Inc. (ZVSA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ZyVersa Therapeutics, Inc. (ZVSA) Healthcare & Pipeline Overview

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for renal and inflammatory diseases. Its pipeline includes VAR 200, a cholesterol efflux mediator targeting conditions like focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease, and IC 100, an inflammasome ASC inhibitor for various inflammatory disorders, operating with a small team in Weston, Florida.

What Is the Investment Thesis for ZVSA?

ZyVersa Therapeutics, Inc. presents an investment profile centered on the potential of its clinical-stage pipeline to address significant unmet medical needs in renal and inflammatory diseases. The company's primary value drivers are VAR 200, a cholesterol efflux mediator targeting focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease, and IC 100, an inflammasome ASC inhibitor for various inflammatory conditions. Growth catalysts are intrinsically linked to the successful progression of these drug candidates through clinical trials, including positive data readouts, achievement of regulatory milestones such as Fast Track or Orphan Drug designations, and eventual regulatory approvals. Furthermore, strategic partnerships or licensing agreements with larger pharmaceutical companies could provide substantial non-dilutive funding and accelerate commercialization. The company's reported market capitalization of $0.00 billion reflects its early-stage nature and the inherent risks. Its beta of 0.79 suggests a historical volatility lower than the broader market. Key risks include the high failure rate of clinical trials, substantial capital requirements for R&D, and intense competition within the biotechnology sector. The thesis hinges on the scientific validation and clinical efficacy of its novel therapeutic approaches.

Based on FMP financials and quantitative analysis

ZVSA Key Highlights

ZyVersa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company with a pipeline focused on renal and inflammatory diseases.

• The company's market capitalization is reported as $0.00 billion, indicating a micro-cap valuation within the biotechnology sector.
• A beta of 0.79 suggests that the stock has historically exhibited lower volatility compared to the overall market.
• The primary drug candidates, VAR 200 and IC 100, are designed to address conditions such as focal segmental glomerulosclerosis, Alport syndrome, diabetic kidney disease, and various inflammatory disorders.
• ZyVersa Therapeutics operates with a lean organizational structure, employing 7 individuals at its headquarters in Weston, Florida.

Who Are ZVSA's Competitors?

ZVSA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZVSA's Key Strengths?

Focused pipeline with two distinct drug candidates (VAR 200, IC 100) targeting significant unmet medical needs.

• Novel mechanisms of action (cholesterol efflux mediator, inflammasome ASC inhibitor) potentially offering differentiated therapies.
• Targeting both rare kidney diseases (FSGS, Alport) and large market opportunities (DKD, general inflammatory diseases).
• Lean operational structure with 7 employees, potentially allowing for agile development.

What Are ZVSA's Weaknesses?

Clinical-stage company with no commercialized products or revenue generation, relying heavily on future pipeline success.

• Small team size (7 employees) may limit the scope and speed of parallel development efforts.
• High capital requirements for R&D and clinical trials, necessitating continuous funding.
• Trades on the OTC market, which typically implies lower liquidity and less stringent disclosure requirements.

What Could Drive ZVSA Stock Higher?

ZVSA catalyst: Announcement of positive clinical trial data for VAR 200 in any of its target indications (FSGS, Alport Syndrome, DKD), which could validate its mechanism and advance its development.

• Regulatory milestones such as the granting of Orphan Drug Designation or Fast Track status for VAR 200 or IC 100, potentially accelerating their development and review timelines.
• Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies for the co-development or commercialization of VAR 200 or IC 100, providing crucial funding and resources.
• Continued advancement of VAR 200 into later-stage clinical trials (e.g., Phase 2 or Phase 3), demonstrating progress towards potential market entry.
• Further preclinical development and characterization of IC 100, establishing its potential for broad application across various inflammatory diseases.

What Are the Key Risks for ZVSA?

Financial-distress signal — its Altman Z-Score of -23.21 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for VAR 200 or IC 100, including lack of efficacy or unexpected adverse events, which would significantly jeopardize the company's future prospects.
• Inability to secure adequate funding for ongoing research and development, clinical trials, and operational expenses, leading to potential delays or cessation of drug programs.
• Intense competition from other biotechnology and pharmaceutical companies developing treatments for renal and inflammatory diseases, potentially eroding future market share.
• Significant regulatory hurdles and potential delays in obtaining necessary approvals from health authorities for its drug candidates, extending time to market and increasing costs.
• Lack of commercial viability or market acceptance for VAR 200 or IC 100, even if approved, due to pricing pressures, competition, or limited physician adoption.

What Are the Growth Opportunities for ZVSA?

• Growth opportunity 1: The development of VAR 200 for Focal Segmental Glomerulosclerosis (FSGS) represents a significant opportunity. FSGS is a rare and severe kidney disease with limited treatment options, often leading to end-stage renal disease. The global market for rare kidney diseases is substantial and growing, driven by increasing diagnosis and the high cost of existing therapies. VAR 200, as a cholesterol efflux mediator, offers a novel mechanism of action that could differentiate it from current treatments. Successful clinical trial outcomes and subsequent regulatory approval could position ZyVersa Therapeutics to address a critical unmet need, potentially capturing a meaningful share of this specialized market within the next five to ten years.
• Growth opportunity 2: Advancing VAR 200 for Alport Syndrome also presents a compelling growth pathway. Alport Syndrome is a genetic disorder characterized by progressive kidney disease, often leading to kidney failure, along with hearing loss and eye abnormalities. There is a pressing need for disease-modifying therapies that can slow or halt the progression of renal damage in Alport patients. The orphan drug designation potential for Alport Syndrome could provide regulatory incentives and market exclusivity. If VAR 200 demonstrates efficacy in clinical trials, it could significantly improve patient outcomes and establish ZyVersa Therapeutics as a key player in the treatment of rare genetic kidney disorders over the coming decade.
• Growth opportunity 3: The application of VAR 200 to Diabetic Kidney Disease (DKD) targets a vast and rapidly expanding patient population. DKD is a severe complication of diabetes, affecting millions worldwide and being a leading cause of chronic kidney disease and end-stage renal disease. A novel cholesterol efflux mediator like VAR 200, if proven effective in clinical trials, could offer a new therapeutic paradigm beyond existing blood pressure and glucose control medications. This broad market potential could provide substantial revenue generation for ZyVersa Therapeutics in the long term, assuming successful development and commercialization.
• Growth opportunity 4: The development of IC 100, a novel inflammasome ASC inhibitor, for a multitude of inflammatory diseases offers broad therapeutic potential. Inflammasomes play a critical role in the pathogenesis of various chronic and acute inflammatory conditions, including autoimmune diseases, metabolic disorders, and neuroinflammatory diseases. The global market for anti-inflammatory drugs is enormous, with continuous demand for more effective and safer treatments. By targeting the inflammasome ASC, IC 100 could address underlying inflammatory mechanisms across multiple indications. Successful preclinical and clinical development could lead to a pipeline of potential therapies, allowing ZyVersa Therapeutics to tap into diverse and lucrative segments of the inflammatory disease market over the next decade.
• Growth opportunity 5: Strategic partnerships and licensing agreements represent a crucial growth opportunity for ZyVersa Therapeutics, typical for clinical-stage biopharmaceutical companies. Such collaborations with larger pharmaceutical companies can provide significant non-dilutive funding, access to extensive development and commercialization resources, and global market reach. These partnerships often involve upfront payments, milestone payments upon achieving specific development or regulatory goals, and royalties on future sales. Securing a favorable partnership for VAR 200 or IC 100 could de-risk the development process, accelerate market entry, and provide substantial financial resources to advance the company's pipeline, potentially within the next three to five years.

What Opportunities Does ZVSA Have?

• Positive clinical trial results for VAR 200 or IC 100 could significantly increase company valuation and attract partnerships.
• Securing strategic partnerships or licensing agreements with larger pharmaceutical companies for late-stage development and commercialization.
• Obtaining Orphan Drug or Fast Track designations for rare disease indications, accelerating regulatory pathways.
• Expansion of pipeline by identifying additional indications for existing drug candidates or developing new ones.

What Threats Does ZVSA Face?

• High risk of clinical trial failures, which could lead to significant delays, increased costs, or termination of drug programs.
• Inability to secure sufficient funding to advance its pipeline through all necessary development stages.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative treatments.
• Regulatory hurdles, delays, or unfavorable decisions from health authorities impacting drug approval timelines.

What Are ZVSA's Competitive Advantages?

• Intellectual property protection, including patents, for its proprietary drug candidates VAR 200 and IC 100.
• Specialized scientific expertise in cholesterol efflux mechanisms and inflammasome inhibition, providing a distinct research focus.
• Potential first-mover advantage in specific therapeutic areas or for particular mechanisms of action if its drugs are novel.
• Addressing significant unmet medical needs in rare kidney diseases and broad inflammatory conditions, which can create strong market demand.

What Does ZVSA Do?

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic products designed to address critical unmet medical needs in renal and inflammatory diseases. Headquartered in Weston, Florida, the company operates with a focused strategy, leveraging a lean team of 7 employees to advance its proprietary pipeline. At the core of its development efforts are two distinct drug candidates: VAR 200 and IC 100. VAR 200 is a cholesterol efflux mediator, a novel approach aimed at treating a spectrum of kidney diseases. Specifically, it is being developed for focal segmental glomerulosclerosis (FSGS), a rare and severe kidney disease characterized by scarring of the kidney's filtering units; Alport syndrome, a genetic disorder leading to progressive kidney disease and hearing loss; and diabetic kidney disease (DKD), a common and serious complication of diabetes. These conditions represent areas with significant patient populations and limited effective treatment options, underscoring the potential impact of VAR 200. The second key asset, IC 100, is a novel inflammasome ASC inhibitor. This compound targets the inflammasome pathway, a crucial component of the innate immune system involved in the pathogenesis of a multitude of inflammatory diseases. By inhibiting the inflammasome ASC, IC 100 aims to mitigate the excessive inflammatory responses that drive various chronic and acute inflammatory conditions. As a clinical-stage entity, ZyVersa Therapeutics' primary activities revolve around rigorous research and development, conducting clinical trials, and navigating the complex regulatory landscape to bring its potential therapies to market. The company's strategic positioning within the biotechnology sector emphasizes addressing specific disease mechanisms with targeted, potentially disease-modifying treatments.

What Products and Services Does ZVSA Offer?

• Develops and commercializes products for the treatment of renal (kidney) diseases.
• Develops and commercializes products for the treatment of inflammatory diseases.
• Engages in the development of VAR 200, a cholesterol efflux mediator.
• VAR 200 is designed to treat focal segmental glomerulosclerosis (FSGS).
• VAR 200 is also being developed for Alport syndrome.
• VAR 200 targets diabetic kidney disease (DKD).
• Engages in the development of IC 100, a novel inflammasome ASC inhibitor.
• IC 100 is being developed for the treatment of a multitude of inflammatory diseases.

How Does ZVSA Make Money?

• Focuses on research and development (R&D) of novel drug candidates through preclinical and clinical trial phases.
• Aims to secure regulatory approvals from health authorities for its therapeutic products.
• Seeks to commercialize approved drugs, potentially through direct sales or strategic partnerships and licensing agreements.
• Relies on external funding, grants, or partnerships to finance its extensive R&D activities and clinical trials.

What Industry Does ZVSA Operate In?

ZyVersa Therapeutics, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on the development of novel therapies for renal and inflammatory diseases. This sector is characterized by extensive research and development, long development cycles, and significant capital investment. Current market trends indicate a growing demand for targeted therapies for chronic kidney diseases, driven by an aging global population and the rising incidence of conditions like diabetes, which often leads to diabetic kidney disease. Similarly, advancements in understanding inflammatory pathways, such as the inflammasome, are opening new avenues for treating a wide array of inflammatory disorders. The competitive landscape includes numerous established pharmaceutical giants with extensive R&D budgets and commercialization capabilities, as well as a multitude of smaller, clinical-stage biotechs vying for market share with innovative drug candidates. ZyVersa Therapeutics positions itself by focusing on specific mechanisms of action, such as cholesterol efflux mediation and inflammasome ASC inhibition, aiming to carve out a niche in areas with significant unmet medical needs.

Who Are ZVSA's Key Customers?

• Patients suffering from focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease.
• Patients afflicted with various inflammatory diseases targeted by IC 100.
• Healthcare providers, including nephrologists and specialists in inflammatory diseases, who prescribe treatments.
• Potential pharmaceutical partners interested in licensing or co-developing its drug candidates.

Company Profile

ZyVersa Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Weston, US. The company is led by CEO Stephen C. Glover. ZVSA has traded publicly since 2022.

How ZyVersa Therapeutics, Inc. Is Valued

Relative to its peer group, ZVSA's quantitative score of 57/100 is below the peer average of 76/100.

Return on equity for ZyVersa Therapeutics, Inc. stands at 0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.3%, showing how much profit it generates from its asset base. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.

ZyVersa Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.21 places it in the distress zone, a signal of elevated financial risk.

ZyVersa Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 62.2% below estimates on average.

Wall Street analysts project ZyVersa Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-65.80.

ZVSA Financials

ZVSA Latest News

No recent news available for ZVSA.

ZVSA Analyst Consensus

ZVSA MoonshotScore

Common Questions About ZVSA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources